Successful autologous skeletal myoblast transplantation into infarcted myocardium in a variety of animal models has demonstrated improvement in cardiac function. We evaluated the safety and feasibility of transplanting autologous myoblasts into infarcted myocardium of patients undergoing concurrent coronary artery bypass grafting (CABG) or left ventricular assist device implantation (LVAD). In addition, we sought to gain preliminary information on graft survival and any potential improvement of cardiac function. Eighteen patients with a history of ischemic cardiomyopathy participated in a phase I, nonrandomized, multicenter pilot study of autologous skeletal myoblast transplantation concurrent with CABG or LVAD implantation. Twelve patients with a history of previous myocardial infarction (MI) and a left ventricular ejection of less than 30% were enrolled in the CABG arm. In a second arm, six patients underwent LVAD implantation as a bridge to heart transplantation and were required to donate their heart for testing at the time of heart transplant. Myoblasts were successfully transplanted in all patients without any acute injection-related complications or significant long-term unexpected adverse events. Follow-up PET scans showed new areas of viability within the infarct scar in CABG patients. Echocardiography measured an average improvement in left ventricular ejection fraction (LVEF) from 25% to 34%. Histological evaluation in four out of five patients who underwent heart transplantation documented survival and engraftment of the skeletal myoblasts within the infarcted myocardium. These interim results demonstrate survival, feasibility, and safety of autologous myoblast transplantation and suggest that this modality may offer a potential therapeutic treatment for end-stage heart disease.
INTRODUCTION
loss of cardiomyocytes and subsequent deterioration in both structure and function of the myocardium. Unlike skeletal muscle, cardiac muscle lacks the ability to re-Congestive heart failure (CHF) remains a leading cause of morbidity and mortality despite continuing ad-generate once injured (14-16). Injured skeletal muscle retains the capacity to repair itself because of existing vances in various treatment options. Despite these advances, there remain a significant subset of patients who cells called myoblasts (8). Dormant skeletal myoblasts, once activated, are able to generate new muscle fibers become refractory or suboptimally respond to current therapy. The impact of CHF spans all ethnic groups and and restore functionality (3). Preclinical data from a variety of animal studies have has profound economic consequences (4, 17) . CHF is caused by myocardial infarction (MI) and results in the demonstrated the ability of skeletal myoblasts to engraft, 12 DIB ET AL.
form myotubes, and enhance cardiac function following Sonos 5500 ultrasound system (Phillips) using standard techniques. Left ventricular ejection fraction (LVEF) transplantation into infarcted myocardium (1, 7, 13, 18) . More recently, preliminary human studies focusing on was calculated by the Simpson rule. patients with ischemic heart failure have demonstrated successful myoblast transplantation into the postinfarc-Myoblast Procurement and Culturing tion scar during coronary artery bypass (6, (9) (10) (11) .
Approximately 2-3 weeks prior to scheduled sur-The purpose of this study was to test the survival, gery, a skeletal muscle biopsy between 2 and 5 g was safety, and feasibility of transplanting autologous myobtained from each patient. The muscle specimens were oblasts derived from skeletal muscle into and around a immediately placed in transport medium, packed in froscarred area of the myocardium, in subjects who are zen gel ice packs, and shipped to the cell processing postmyocardial infarction with left ventricular dysfuncfacility (Diacrin, Inc.). During processing, connective tion. The transplant of the autologous myoblasts was tissue was removed from each specimen and the rest of performed during coronary artery bypass surgery (CABG) the muscle tissue was minced into a slurry. The slurry or left ventricular assist device implantation (LVAD).
underwent several cycles of enzymatic digestion at 37°C MATERIALS AND METHODS with trypsin/ethylenediaminetetraacetic acid (EDTA) (0.5 mg/ml trypsin, 0.53 mM EDTA; Gibco BRL) and Study Design and Patient Eligibility collagenase (0.5 mg/ml; Gibco BRL) to release satellite This phase I, prospective, nonblinded, multicenter cells. Skeletal myoblasts were cultured according to a clinical trial was designed to enroll 18 patients. Feasibilmodified Ham's method (16) . The satellite cells were ity and safety of myoblast transplantation was assessed plated and grown in myoblast basal growth medium in 12 patients who were candidates for elective CABG.
(SkBM; Clonetics), which contained 15-20% fetal bo-Feasibility and engraftment were evaluated in six pavine serum (Hyclone), recombinant human epidermal tients undergoing LVAD as a bridge for heart transplant.
growth factor (10 ng/ml), and dexamethosone (3 µl/ml). Eligibility criteria for the CABG group included previ-To prevent myotube formation during the culture proous MI and left ventricular ejection fraction less than cess, cell densities were maintained throughout the pro-30%. Patients who required left ventricular aneuryseccess at less than 80% confluency. Myoblasts were extomy were included. Eligibility criteria for the LVAD panded for 11-13 doublings, harvested, and cryopreserved arm included patients undergoing LVAD as a bridge for before transplantation. Myoblasts were thawed, washed, heart transplant and who were willing to donate their and resuspended in transplantation medium at approxiheart after heart transplant for histological examination.
mately 100 million cells per ml, loaded into 1-cc tuber-Patients with skeletal muscle disease, active malignancy, culin syringes, chilled to 4°C, and shipped on ice to the recent history of alcohol or drug abuse, pregnancy, or clinical center for transplant. At the time of transplant, active infection were excluded. This study was concells were warmed to room temperature and were ready ducted in accordance with good clinical practices, was for injection. approved by the Food and Drug Administration under an investigational new drug application, and approval Myoblast Transplantation was obtained by each site's institutional review board.
At the time of surgery, the cultured myoblasts were Baseline Testing injected into the epicardial surface of the infarcted area Suitable patients underwent screening and baseline using an escalating dose regimen. All patients underwent evaluations, which consisted of a physical examination, CABG or LVAD implantation concurrent with myoblast electrocardiogram, 24-h Holter monitoring, and routine transplantation. In the CABG group, 12 patients were blood testing. Transthoracic echocardiography and sindivided into four escalating dose groups (three patients gle photon emission computed tomography (SPECT) per group) of 10 × 10 6 , 30 × 10 6 , 100 × 10 6 , and 300 × were used to assess global left ventricular function, is-10 6 cells. The cell dose for LVAD patients was 300 × chemia, and viability, respectively. Optional magnetic 10 6 cells, except for one patient who received only 2.2 resonance imaging (MRI) and 18 F-FDG positron emismillion cells. Autologous myoblasts were injected into sion tomography (PET) were used to assess scar segand around the area of infarction from the epicardial surment thickness and myocardial viability, respectively.
face over a period of 15 s, using 3-30 injections of 0.1 Procedures for SPECT, 24-h viability imaging, and PET ml at a concentration of 100 million cells per ml, with cardiac imaging have been previously established (2). the exception of group 1 (10 × 10 6 ) patients, who re-Echocardiography ceived three injections of 3.3 × 10 7 /ml. Cell injections did not overlap and were performed on a beating heart Global and regional ventricular wall contractility was measured by two-dimensional echocardiography with a that was on pump. Excised myocardium obtained from the explanted hearts of LVAD patients was fixed in formalin and embedded in paraffin; 5-µm sections were obtained and stained with trichrome.
The myoblast cultures were made between 11 and 13 doublings with an average doubling time of 24 h. Analy-Statistical Analysis sis of the cultures prior to transplantation by phase con-The primary outcome measure was the incidence of trast microscopy showed single cells and no fused multiadverse events. In addition, we assessed changes in echonucleated myoblasts. There was no bacterial or fungal cardiogram measures among the patients with CABG. contamination as determined by USP sterility and myco-Mean levels at 12 weeks were compared to those at plasma testing. In all but one case that required early baseline, and the statistical significance was calculated surgery, growth of the number of target cells was by using the paired t-test. The 12-week observation time achieved. Purity of the myoblast preparation, based on was specified prior to examining the data. Missing data anti-CD-56 mAb staining and fluorescence activated were attributed to failures to record observations, or to cell-sorting analysis, ranged from 43% to 98% (mean = missed appointments, and were assumed to be missing 76%). Trypan blue viability testing of the injected cells at random.
at the time of transplant varied from 85% to 98%.
RESULTS

Adverse Events Study Group
A summary of adverse events is presented in Table  A total of 18 patients were enrolled in the study and 2. For both the CABG and LVAD groups the transplant underwent myoblast cell transplantation concurrent with procedure was clinically well tolerated and the myoblasts CABG or LVAD. Baseline demographics of CABG pawere delivered successfully. No deaths or arrhythmias tients are shown in Table 1 . Twelve patients with a mean occurred during the surgery or injection of the cells. age of 56.5 years (range 33-75) were enrolled in the Minimal bleeding was seen on occasion from the injec-CABG arm. Patients received an average of 2.8 bypass tion sites. grafts; 9 out of 12 had left internal mammary grafts and
In the CABG group, three patients in each escalating 2 patients had a left ventricular aneurysectomy procedose group received 10 × 10 6 , 30 × 10 6 , and 100 × 10 6 dure. Six patients, mean age of 56 years (range 43-65), and 300 × 10 6 . As of August 1, 2003, follow-up examiunderwent LVAD implantation as a bridge to heart nations as long as 24 months (minimum = 8 months, transplant. Four patients in the CABG group showed mean = 17.5 months) postprocedure have been comnonsustained ventricular tachycardia (NSVT) on basepleted. Importantly, there was no mortality and no eviline Holter monitoring, which persisted on follow-up dence of infection at any time after the transplant as Holter monitoring after cell transplantation.
determined by fever or elevated white blood counts. One patient who received a dose of 100 × 10 6 cells experi-Cell Culturing enced multiple episodes of symptomatic NSVT 7 days postsurgery. The patient was hospitalized and an angio-There were no serious complications related to biopsy procurement; however, all patients experienced gram was performed. Two areas of stenosis, 70% and 60%, were found in the left internal mammary artery mild discomfort and one patient had a small hematoma. cardium that received transplant injections clearly demonstrated engraftment of striated myotubes containing multiple nuclei developing within the fibrotic tissue with no evidence of lymphocyte infiltration (Fig. 1 ). There graft. Coronary flow reserve assessed by Doppler FloWire was reduced to 1.5, indicating ischemia. Electrophysiol-was no evidence of myoblast migration into normal myocardium. Immunostaining with the MY-32 antibody ogy studies demonstrated inducible sustained monomorphic ventricular tachycardia. Treatment included an in-(a skeletal muscle reactive anti-myosin that does not stain cardiac muscle) confirmed myoblast engraftment. creased dose of beta-blockers and placement of an internal cardioverter-defibrillator (ICD). No further ar-Verification of engrafted myofibers was visualized in all LVAD recipients, except the first patient who received rhythmias were observed up to 9 months follow-up. PET scan revealed improvement in the uptake of (18)-fluoro-only 2.2 million cells and a single patient who remains alive and stable but has not received a transplant. 2-deoxyglucose (FDG) in the scar area.
One patient who had a previously received cardiac Functional Assessment resynchronization therapy with ICD prior to cell transplant experienced two episodes of ICD firing 9 months PET scanning, which was optional, was performed on seven patients at baseline and month 6 follow-up. posttransplantation. This was likely due to sustained ventricular arrhythmias but could not be confirmed by Evidence of cell viability in the region of the myocardial scar after myoblast transplantation was seen in three pa-device interrogation. Follow-up evaluation revealed proper functioning of the device. Although we cannot exclude tients. For two patients who received 10 × 10 6 cells, the PET scan showed no improvement. One out of two pa-the possibility that ICD firing was related to myoblast engraftment, alterations in his medical management tients who received 100 × 10 6 cells and two out of three patients who received 300 × 10 6 cells showed an in-were made and no further events were reported. These events were considered by the data safety monitoring crease in FDG uptake in the transplanted zone. A representative horizontal long axis PET scan from a high-board to be unrelated to the cell transplant.
In the LVAD group, one patient received 2.2 million dose patient is shown in Figure 2 . SPECT analysis, which was optional, was performed on seven patients. Evi-cells due to deterioration of cardiac function and only 2.2 million cells were available for transplantation at the dence of reperfusion was observed all patients who received CABG (Fig. 2) . Cardiac MRI in four out of four time needed. The other five patients received 300 × 10 6 cells. The patients were followed for an average of 4 patients showed an increase in the myocardial thickness of the injected areas, by an increment of approximately months prior to undergoing heart transplantation.
Two deaths occurred in the LVAD implantation 3 mm (Fig. 3) . Individual LVEF for each patient and their corre-group. One death, due to LVAD infection and sepsis, occurred 68 days postprocedure. Autopsy revealed obvi-sponding cell dose are shown in Figure 4 . The NYHA classification at baseline and 12 weeks follow-up was DISCUSSION 2.2 and 1.3 (change: −0.9 ± 1.3, p = 0.04), respectively (Table 3) . This result indicates symptomatic improve-
The main findings of this study can be summarized as: epicardial transplantation of autologous skeletal my-ment. The mean baseline LVEF, measured by echocardiogram, for the CABG patients was 25% prior to trans-oblasts is feasible and safe in that there were no deaths directly related to transplantation and no infections or plantation and 34% at 12 weeks follow-up (change: 9 ± 12, p = 0.04). The average left ventricular systolic and allergic reactions resulting from the procedure or the myoblast preparation. Myoblast transplantation in com-diastolic volumes decreased from an average of 156 to 113 ml (change: −43 ± 64, p = 0.13) and from 224 to bination with bypass surgery led to an increase in left ventricular ejection fraction, an increase in tissue viabil-174 ml, respectively. Left ventricular average systolic and diastolic dimensions decreased from 5.8 to 5.2 cm ity (PET scanning), and reduction in ventricular systolic and diastolic volume (ECHO). The most serious adverse (change: −0.59 ± 0.78, p = 0.07) and from 6.6 cm to 6.2 cm (change: −0.41 ± 0.54, p = 0.07), respectively. event that the safety monitoring board determined could have been possibly related to the cell transplant was nonsustained ventricular tachycardia. This occurred in only 1 out of 12 CABG patients and was effectively treated with medications and an ICD. Previous experience of autologous myoblast transplantation noted the occurrence of ventricular arrhythmias in 4 out of 10 patients between days 9 and 22 (10). Patients were successfully treated with amiodarone and an ICD. Although the exact mechanism of these arrhythmias could not be identified, several considerations were proposed. Potential causes included toxicity due to the large cell dose relative to the scar area, a difference in the action potential between the engrafted tissue and the normal cardiac tissue, cell characteristics (purity, viability, and potency), or inflammation at the site of injection secondary to cell death. It has been reported that up to 90% of cells die ventricular tachycardia; however, likely candidates in-this occurrence. Future studies should include a more thorough investigation of these possibilities and longer clude differences in the cell dose, the injection protocol, and the tissue culture conditions. follow-up. The CABG patients that consented to SPECT analy-Histological analysis in patients in the LVAD group confirmed graft survival in scarred myocardial tissue, sis showed improved perfusion throughout most of the ventricular wall. As these patients also underwent con-minimal localized migration of myoblasts, the absence of tumor formation, and no lymphocyte invasion of nor-current revascularization, it is not possible to attribute the enhanced blood flow solely to the transplant. My-mal tissue or grafted tissue ( Fig. 1) . Although we were unable to check for migration or tumor growth in loca-oblasts themselves do not possess any known ability to differentiate into endothelium required for capillary de-tions outside of the heart, given the autologous nature of the myoblasts and their natural propensity to remain in velopment. Interestingly, anti-CD31 (human endothelial cells) staining of infarcted regions that have been trans-a nondividing state, there is no overt reason to expect 
